Biogen is moving to scale back its real estate footprint in Kendall Square and in Weston, as the Cambridge-based biotech company aims to cut $1 billion in costs in the wake of a disastrous rollout of its Alzheimer’s drug Aduhelm.
Biogen is looking to sublease more than 183,000 square feet at 300 Binney St. in Cambridge — across the street from its headquarters — and is also subleasing two floors, or 80,000 square feet, at one of its two properties at 133 Boston Pond Road in Weston.
Biogen leases a combined 1.157 million square feet across the Commonwealth, and owns an additional 508,000 square feet in Cambridge. It has long subleased one of its two Weston buildings to job-search website Monster.
Create a display name to comment
This name will appear with your comment
